Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBA-Itraconazole in Basal Cell Carcinoma Nevus Syndrome
NCT02354261Phase 2Completed
- Sponsor
- Inhibitor Therapeutics, Inc.
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SUBA itraconazole in basal cell nevus syndrome (BCNS), sponsored by Inhibitor Therapeutics, Inc. Primary endpoint: Response rate of BCC lesions up to 26 weeks. Started Aug 2015; status: completed.
02
Drugs
SUBA itraconazole
03
Conditions
basal cell nevus syndrome (BCNS)
Beyond the preview
Go deeper on NCT02354261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354261.